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Antidiabetogenic Features of 
Benzimidazoles
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and Olga N. Zhukovskaya
Abstract
Literature data on the insulinogenic effect of 2-aminobenzimidazole prompted us 
to investigate its novel derivatives, particularly those containing an additional fused 
cycle in C1,2-α position, including imidazole, dihydroimidazole, or tetrahydropy-
rimidine ring. Consensus analysis of the hypoglycemic effect of these compounds 
performed with IT Microcosm and PASS system revealed that activity is mostly char-
acteristic for N9-2,3-dihydroimidazo[1,2-a]benzimidazole derivatives. Substructural 
analysis of hypoglycemic activity identified substituents that determine the greatest 
pharmacological effect. According to the in silico assessment of the ADME proper-
ties, RU-254 was nominated as a lead compound due to the most optimal calculated 
and experimental activity and pharmacokinetic parameters. Preclinical studies 
have shown that identified compound has a pronounced insulinogenic effect and 
hypoglycemic effect, both in intact animals and in animals with experimental 
diabetes mellitus. RU-254 also reduces the level of glycated hemoglobin upon chronic 
administration, slightly decreases the activity of DPP-4, and increases the average 
number of Langerhans islets in the pancreas. Pharmaceutical drug formulation of 
RU-254 was developed and investigated for pharmacokinetic, pharmacodynamic, 
and toxicological properties. The dosage form of the drug under the name limiglidol 
(compound RU-254, diabenol) was evaluated in the full cycle of clinical studies that 
confirmed the safety, tolerability, and prominent antidiabetic properties of the drug.
Keywords: in silico, IT Microcosm, consensus prediction, antidiabetic effect,  
aminobenzimidazoles, cyclic benzimidazoles, pharmacodynamics, 
pharmacokinetics, toxicology, diabenol
1. Introduction
The history of drug discovery for the treatment of diabetes mellitus was and 
still is strongly determined by achievements in the field of fundamental medicine. 
Initially, the role of the pancreas and islets of Langerhans in the development of this 
pathology was proved; later, the structure of insulin, insulin receptor, and glucose 
transporters was deciphered; the role of the liver glycogenolysis and gluconeo-
genic enzymes, contributing to increased glucose output and hyperglycemia, was 
established; molecular mechanisms for the development of insulin resistance, the 
importance of the incretin system and Na+/glucose transporters in the kidneys, 
and intestinal α-glucosidase were revealed, which led to the introduction of novel 
antidiabetic drugs into clinic [1–4].
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The basis of insulin resistance at the cellular level primarily resides in the 
disruption of insulin signaling pathway at the level of the insulin receptor and 
insulin receptor substrate (IRS) proteins. The underlying mechanism of this 
phenomenon is impaired phosphorylation of serine amino acid residues, catalyzed 
by a number of intracellular protein kinases. The muscles, liver, and adipose tissue 
are the primary target organs of concern for the development of insulin resistance 
[5]. It was established that the severity of insulin resistance correlates, first of all, 
with intracellular lipid accumulation [6]. It is intracellular lipids that hamper signal 
transmission from the insulin receptor and cause a decrease in insulin-dependent 
glucose uptake. The pivotal role of AMP-dependent protein kinase (AMPK), which 
is an energy “sensor” of the cell, is also established, since AMPK through TORCI, 
the first mTOR-based protein complex, serves as a metabolic switch between cata-
bolic and anabolic processes of the cell. Metformin is a biguanide derivative, which 
is the first-line drug for the treatment of type 2 diabetes. In 2001, it was shown that 
the molecular mechanism of its action is at least in part mediated by AMPK [7]. It 
is believed that indirect activation of AMPK by metformin-induced Ser172 phos-
phorylation determines its pleiotropic effects [8].
At the same time, it is important to note that course of type 2 diabetes mel-
litus characterized by several consecutive phases. It begins with primary insulin 
resistance and compensatory hyperinsulinemia with the subsequent development 
of β-cell dysfunction, thus creating the need for administration of insulin secreta-
gogues or insulin formulations at the late stages of the disease [9–11].
Given that the previous works described the insulinogenic effect of the anti-
helminthic drug mebendazole [12], which can be considered as a new scaffold 
(2-aminobenzimidazole or cyclic guanidine) that exhibits an insulinogenic effect, 
we performed an experimental study of the novel cyclic guanidine derivatives, 
designed by introduction of additional fused cycle (imidazole, dihydroimidazole, and 
tetrahydropyrimidine).
2. Results
The synthesis of novel 2-aminobenzimidazole (AmBI) [13, 14] derivatives and 
fused benzimidazole derivatives was carried out, including N9-imidazo[1,2-a]
benzimidazoles (N9-ImBI) [15–17], N1-imidazo[1,2-a]benzimidazoles (N1-
ImBI) [18, 19], N9-2,3-dihydroimidazo[1,2-a]benzimidazoles (N9-DhImBI) [20, 
21], N1-2,3-dihydroimidazo[1,2-a]benzimidazoles (N1-DhImBI) [18, 19], and 
2,3,4,10-tetrahydropyrimido[1,2-a]benzimidazoles (PrmBI) [22–24].
In order to identify the most promising antidiabetic substances using IT 
Microcosm [25, 26] and PASS computer systems [27, 28], a step-by-step detailed in 
silico analysis of the hypoglycemic properties of the new compounds was carried 
out. Programs DruLiTo [29] and QikProp [30] were employed to assess key ADME 
properties and characteristics.
Hypoglycemic effect of the newly obtained derivatives was initially studied in 
rats upon intraperitoneal administration at a dose of 50 mg/kg. Blood sampling was 
carried out 4 hours after treatment with test compounds. Blood glucose concentra-
tion was determined with the glucose oxidase method using a commercial Glucose 
FKD kit [31]. The ratio of glucose concentrations in the blood plasma of the 
experimental and control group animals served as an indicator of hypoglycemic 
activity [32].
It was found that among condensed benzimidazole derivatives, a number of 
substances exceeded hypoglycemic activity of metformin, which served as a refer-
ence drug.
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2.1 In silico study
IT Microcosm [25, 26] and PASS [27, 28] computer systems were employed 
to determine the most promising chemical class of compounds. A training set of 
known hypoglycemic drugs and a library of tested benzimidazole derivatives were 
subjected to a consensus prediction of the level of hypoglycemic activity. The aver-
age informativity coefficient KPr was calculated and used as a metric for comparison 
of AmBI, N9-ImBI, N1-ImBI, N9-DhImBI, N1-DhImBI, and PrmBI derivatives. KPr 
value ranges from 0 for inactive compounds to 5 for highly active compounds.
According to value of KPr, the potential of benzimidazole derivatives classes 
as sources of substances with hypoglycemic activity decreases in the following 
order: N9-DhImBI (KPr = 4.50) > PrmBI (KPr = 4.25) > AmBI (KPr = 2.50) > N
1-ImBI 
(KPr = 2.00) > N
1-DhImBI (KPr = 1.25) > N
9-ImBI (KPr = 0.25) [33].
Thus, it was shown that N9-2,3-dihydroimidazo[1,2-a]benzimidazole and 
2,3,4,10-tetrahydropyrimido[1,2-a]benzimidazole derivatives have the most promising 
blood glucose lowering activity. That is, these tricyclic structures containing embedded 
guanidine group turned out to be more active than 2-aminobenzimidazole derivatives.
Subsequently, employing substructural analysis [34] and analysis via median 
[35] and supremal [36] estimates, the class of N9-2,3-dihydroimidazo[1,2-a]benz-
imidazoles was selected as the most promising for the development of hypoglyce-
mic compounds (Figures 1 and 2). It was shown that this scaffold is more preferable 
than 2,3,4,10-tetrahydropyrimido[1,2-a]benzimidazole.
Substructural analysis [34] of the level of hypoglycemic activity among the N9-2,3-
dihydroimidazo[1,2-a]benzimidazole derivatives allowed us to reveal a chemical feature 
(substituent) that largely determines high hypoglycemic activity—diethylaminoethyl 
substituent at the N9 atom of the N9-DhImBI scaffold.
According to the frequency analysis of physicochemical parameters [37] of 
experimentally studied derivatives of N9-DhImBI scaffold, a significant feature of 
high hypoglycemic activity was revealed—a charge on the internal imidazole cycle 
of the condensed system, namely, Q(Imid1)cs ≥ −0.109, which is a characteristic for 
compound RU-254 (diabenol).
Taken together, the results of a complex consensus in silico analysis of the 
hypoglycemic activity of six classes of benzimidazole derivatives revealed 9-dieth-
ylaminoethyl-2,3-dihydroimidazo[1,2-a]benzimidazole dihydrochloride (RU-254, 
diabenol) as the most promising highly active compound.
To assess the feasibility of a further study of the pharmacological properties of 
compound RU-254, we calculated parameters of drug-likeliness and ADME proper-
ties (absorption, distribution, metabolism, excretion) for RU-254 and reference 
antidiabetic drugs metformin and glibenclamide.
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Using the DruLiTo program [29], it was found that diabenol satisfies the bound-
ary conditions of all eight drug-likeliness filters, while metformin and gliben-
clamide correspond only for two of them.
Water solubility, serum albumin binding parameters, cellular permeability, 
and absorbability through the gastrointestinal tract for the three aforementioned 
substances were calculated with QikProp program [30]. A comparative analysis of 
the obtained characteristics showed that water solubility and the degree of bind-
ing to serum albumin of diabenol are higher than that of glibenclamide and lower 
than that of metformin. Indicators of bioavailability and absorbability through the 
gastrointestinal tract in diabenol are higher than that of glibenclamide and metfor-
min. Thus, in terms of the total pharmacokinetic characteristics calculated in the 
QikProp program, diabenol is superior to metformin and glibenclamide. It should 
be noted that the calculated values of pharmacokinetic parameters of all three 
compounds are in the ranges that are recognized as appropriate for drug molecules.
Summarizing the results of the evaluation of ADME properties obtained using two 
computational approaches, it can be argued that diabenol in regard of its calculated 
drug-like and pharmacokinetic characteristics is not inferior to metformin and gliben-
clamide and is a very promising substance for performing advanced preclinical studies.
Figure 2. 
Supremal evaluations of the effect of basic benzimidazole structure on high hypoglycemic activity level.
Figure 1. 
Informativity coefficients describing the influence of basic benzimidazole structure on high hypoglycemic 
activity level (according to the substructural analysis).
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2.2 Synthesis
Synthesis of 9-diethylaminoethyl-2,3-dihydroimidazo[1,2-a]benzimidazole 
dihydrochloride (RU-254, diabenol) is readily realized through condensation of 
2-amino-1-diethylaminoethylbenzimidazole with an excess of dibromoethane and 
subsequent transformation of the resulting of 9-diethylaminoethyl-
2,3-dihydroimidazo[1,2-a]benzimidazole dihydrobromide to the base and the 
desired dihydrochloride [21].
Example. A stirred suspension of 69.6 g (0.3 mol) of 2-amino-1-diethylamino-
ethylbenzimidazole (I) in 104 ml (1.2 mol) of dibromoethane is gently heated in a 
glycerin bath. At 60–70°C, the initial amine dissolves completely, and at 100–105°C, 
an exothermic cyclization reaction occurs (the bath is set aside at the beginning), 
accompanied by strong boiling up of the reaction mass while temperature rises 
to 140°C and a heavy colorless precipitate begins to form. After 5–7 minutes, the 
reaction virtually ends, and, in order to complete it, the mixture is heated for an 
additional 20 minutes at 140–145°C. After that, 80 ml of DMF are added to the thick 
mass with vigorous stirring, and the mixture is heated for another 10–15 minutes. 
Cooling to 20–25°C, filtering the precipitate, and washing with DMF (3 × 20 ml) 
and acetone (3 × 25 ml) afford 106 g of dihydrobromide (II) in 84% yield. The latter 
is dissolved in 230 ml of water and boiled for 10 minutes with 3–5 g of activated 
carbon. Carbon is filtered off, and the filtrate after cooling is brought to pH 10 with 
40% sodium hydroxide solution. The light yellow oil (III) which separates on the 
surface is extracted with toluene. The toluene extracts are washed with water and 
dried with anhydrous potassium carbonate. The desiccant is filtered off and washed 
with toluene. Combined toluene fractions are acidified by gradual addition of a 
saturated solution of hydrogen chloride in 2-propanol to pH 1. The heavy colorless 
precipitate of dihydrochloride (IV) is filtered off after 4–5 hours at 20–25°C, washed 
with acetone, and dried at 100–110°С for 2–3 hours to a constant weight. Yield is 75 g 
(90.9%) from dihydrobromide (III) and 75% from the initial amine (II). The crude 
product can be recrystallized from 2-propanol to pharmacopeia grade purity.
2.3 Preclinical studies
Diabenol had a pronounced hypoglycemic effect and antihyperglycemic activ-
ity in carbohydrate tolerance tests performed on white outbred rats and rabbits. 
The compound studied showed a marked decrease of glycemia in animals with 
impaired glucose tolerance (in rats with severe streptozotocin diabetes and insulin 
resistance syndrome), in rats with alloxan diabetes, and in rabbits with acute 
insulin deficiency, induced with administration of anti-insulin guinea pig serum. 
In experiments on pancreatomic dogs, diabenol did not reduce blood glucose but 
enhanced the hypoglycemic effect of exogenously administered insulin [38–40], 
thus confirming insulin-mediated mechanism of action.
Detailed study of antidiabetic action revealed not only pancreatotropic but 
also extrapancreatic components of diabenol action. Its pancreatotropic effect is 
determined by the enhancement of phase 1 insulin secretion, especially in glucose-
stimulated conditions (Figures 3 and 4).
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Figure 4. 
Effect of diabenol (10 mg/kg, intravenously) on the basal portal vein blood glucose levels in cats [38].
Diabenol increases the insulin-dependent glucose uptake in muscles of rat 
diaphragm. Under conditions of alloxan-induced diabetes in rats, diabenol restored 
liver glycogen content and glycolysis rate and inhibited glycogenolysis in insulin-
dependent organs and tissues (liver, striated muscles) while having no significant 
effect on these parameters in kidneys, which are insulin-independent organs [38].
It could be assumed that increased insulinotropic effect of diabenol is associated 
with a possible incretinomimetic effect. Studies [41] showed the ability of diabenol 
to inhibit the incretin-degrading DPP-4 enzyme, leading to a modulation of the 
insulin response. In our studies, diabenol also inhibited DPP-4, but in substantially 
higher concentrations (IC50 1.35–2.05 mM), which cannot be achieved in the 
animal’s body. Along with that, a 28-day administration of diabenol to rats with 
streptozotocin-induced diabetes was found to slightly and statistically insignifi-
cantly decrease the plasma activity of DPP-4 [42], which could be attributed to the 
action of its metabolites.
Figure 3. 
Effect of diabenol (10 mg/kg, intravenously) in blood insulin levels during glucose tolerance test (1 g/kg) in 
cats.
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Long-term administration of diabenol to streptozotocin-nicotinamide-induced 
diabetic rats allowed us to obtain interesting and valuable results. Oral administra-
tion of diabenol in a dose of 25 mg/kg for 4 weeks reduced blood glucose levels 
and volume of consumed liquid by more than 2 times, and level of glycated hemo-
globin by 2.2%, and increased the content of C-peptide [43]. Moreover, diabenol 
administration resulted in a significant increase in the average number of islets of 
Langerhans in the splenic region of the pancreas and a significant increase in the 
area of the pancreatic β-cells (Table 1) [44].
The studied compound did not affect the apoptosis index (fraction of caspase-3 
positive cells) and the proliferation index (PCNA-positive and Ki-67-positive cells) 
of the endocrinocytes of Langerhans islets. That is, diabenol had a cytoprotective 
effect on the cells. These data confirm the possibility of increasing the synthetic 
activity of β-cells under the influence of diabenol [44].
Given the complex nature of type 2 diabetes mellitus and aiming to increase the 
effectiveness of antidiabetic therapy in clinical practice, combination drugs (fixed 
combinations) are actively used to simultaneously target several key pathogenesis 
factors of the underlying disease or its complications [7, 9]. The optimal ratios of 
diabenol with metformin (1:4) and glibenclamide (5:1) were determined in experi-
ments on rats with streptozotocin-nicotinamide-induced diabetes. Administration 
of these fixed combinations proved to be effective in terms of key metabolic mark-
ers, including blood glucose level, dynamics of glycated hemoglobin reduction, 
C-peptide level, and recovery of pancreatic β-cells, and has a positive impact on 
carbohydrate metabolism—liver glycogen content and glycogenolysis [45].
A very important aspect of diabetes pathogenesis is the activation of lipid 
peroxidation, which facilitates development of β-cell dysfunction and peripheral 
insulin resistance [11]. In order to address this issue in clinical practice, combination 
therapy regimens for diabetes have begun to include an antioxidant, for example, 
lipoic acid [46]. At the first stage of our study, the direct effect of some antidiabetic 
agents on free radical processes was studied in vitro. It was established that diabenol 
is a scavenger of superoxide anion, hydroxyl, and peroxyl radicals; rosiglitazone 
is active only against the superoxide anion, gliclazide has an antiradical effect 
in experiments with DPPH, and metformin and glibenclamide were unable to 
interfere with these processes. At the same time, the established direct antioxidant 
properties of some studied drugs are difficult to be expected in vivo, since they 
require relatively high concentrations to exert antiradical activity in vitro [47, 48].
Experimental 
groups
Islet area (μm2) Volume 
fraction of 
islets (%)
Relative 
number 
of β-cells 
(%)
Volume 
fraction 
of β-cells 
(%)
Nuclear 
area of 
β-cells 
(μm2)
Intact control 15,448.2 ± 9819.4 11.0 ± 1.2 63.8 ± 7.2 74.2 ± 5.6 26.4 ± 3.7
Streptozotocin-
nicotinamide-
induced diabetes
12,801.5 ± 11,252.3 5.1 ± 2.3* 47.1 ± 3.5* 55.3 ± 6.1* 30.5 ± 6.2
Streptozotocin-
nicotinamide 
induced diabetes 
+25 mg/kg 
diabenol
9559.6 ± 11,513.8 7.5 ± 1.5 54.3 ± 9.5 63.1 ± 4.6 25.4 ± 6.4
*Statistically significant compared with the intact control group.
Table 1. 
Morphometric parameters of pancreatic islets in splenic region of the pancreas of streptozotocin-nicotinamide-
induced diabetic rats after administration of diabenol for 21 days (M ± m) [44].
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A further study [48] determined the optimal ratios for a combination of dia-
benol and lipoic acid (2.8: 1 and 5.6: 1). Its activity was studied in a streptozotocin-
nicotinamide-induced diabetic rat model. It was established that this combination 
possesses a more pronounced antidiabetic effect than monotherapy with diabenol. 
The more important finding of this study is a significantly reduced content of lipid 
peroxidation products in the liver, pancreas, and kidneys. In the pancreas under 
streptozotocin intoxication conditions, β-cells were significantly preserved by the 
combined treatment with diabenol and lipoic acid.
It is known that diabetes is associated with the increased thrombogenic potential 
of the blood and impaired rheology properties [49]. This effect is attributed not 
only to hyperosmolarity of the blood due to hyperglycemia but also to an increased 
aggregation of platelets and red blood cells. Among the antidiabetic agents used in 
clinical practice, only gliclazide has a direct inhibitory effect on platelets [8]. For 
other drugs, a similar effect is observed only with prolonged therapy. Given the fact 
that diabetes increases the frequency of thrombosis events, we studied the effect of 
diabenol on aggregation properties of platelets and red blood cells and its influence 
on microcirculation in experimental diabetes.
It was established that diabenol, both in vitro and in the conditions of the whole 
organism, has an antiplatelet activity. Probably, the effect on functional activity 
of platelets is determined by the influence of diabenol on balance of prostacyclin 
and thromboxane A2 systems. Diabenol showed an antithrombogenic effect on 
the model of thrombosis of the carotid induced by electric current and in systemic 
adrenaline-collagen thrombosis, exceeding the activity of gliclazide [50–52].
Diabenol reduced the aggregability and increased the erythrocyte deformability 
in normal conditions and, more profoundly, in experimental diabetes. Using fluo-
rescent probes, it has been shown that diabenol was able to increase electronegativ-
ity and reduces the microviscosity of the red blood cells membrane, which results in 
the increase in their deformability [53–56].
Amelioration of thrombogenic potential and blood viscosity gives diabenol abil-
ity to enhance the survival of skin graft (a model of the diabetic foot) in both intact 
and alloxan-induced diabetic animals [57].
Toxicological study of the diabenol pharmaceutical substance and the dosage 
form (tablets containing 0.2 g of the active ingredient) involved acute and chronic 
toxicity, examination of cumulative properties, immunotoxicity, effects on carcino-
genesis, and transplacental action. The therapeutic dose of the drug had no adverse 
effects. Subtoxic doses of diabenol lead to a sharp decrease in pancreatic β-cell 
secretion along with platelet hemorrhages.
Upon long-term administration of diabenol to low-cancer NMRI mice, trans-
genic HER-2/neu mice, and LIO rats with drinking water, no toxic or carcinogenic 
effect was observed. An interesting fact has been demonstrated, that is, in NMRI 
mice, diabenol delayed the development of age-related disorders of the extra func-
tion and increased the life span of animals. The drug inhibited the occurrence of 
spontaneous tumors, reduced the incidence of malignant lymphomas, and inhibited 
the onset and development of colon cancer induced with 1,2-dimethylhydrazine in 
rats. The authors of this study conclude that diabenol has an anticarcinogenic and 
geroprotective effect. Hence, both diabenol and metformin contain a guanidine 
group in their structure and exert experimentally proven antitumor effect and 
geroprotective activity [58–60].
The data on the pharmacokinetic study of diabenol established the values of the 
drug half-life and average retention time, which suggest that the substance undergoes 
significantly rapid elimination. The drug penetrates well into organs and tissues, 
especially in those with a high degree of vascularization. An important role in the 
processes of elimination of a compound is played by processes of its metabolism [61].
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2.4 Clinical studies
Clinical studies of diabenol were conducted on 180 patients with type 2 diabetes. 
The drug was administered orally in solid dosage form (0.2 g tablets) 2 times a 
day. The study design was a randomized controlled comparative study of efficacy, 
tolerability, and safety. Glidiab (gliclazide) served as a reference drug. The course 
of diabenol administration ameliorated both fasting and postprandial hypergly-
cemia, reduced glycated hemoglobin level by 1.1% at the end of the third month, 
and increased postprandial insulin levels. Diabenol reduced platelet aggregation, 
increased erythrocyte deformability, and reduced their aggregability, thus normal-
izing coagulation hemostasis [62, 63].
Clinical and laboratory parameters of patients allowed to conclude that diabenol 
administered in a dose of 0.4 g per day for 3 months had no adverse or toxic effects [63].
3. Conclusions
Based on the studies performed, it can be stated that aminobenzimidazole is a uni-
versal privileged substructure that can be used as a source for development of novel 
antidiabetic agents. Introduction of structural modifications by means of transition 
to tricyclic structures led us to the identification of N9-2,3-dihydroimidazo[1,2-a]
benzimidazole as an optimal scaffold, and in this chemical class of compounds, 
agents with high glucose lowering activity were identified.
As a result, RU-254, or diabenol, was developed as the most active compound. 
Both in the experimental and clinical settings, it restores insulin secretion and ame-
liorates peripheral tissue glucose uptake. Another important effect of diabenol that 
has been established experimentally and confirmed in clinical studies is a reduction 
of thrombogenic potential and viscosity of blood. It has been demonstrated that 
diabenol, much like the biguanide derivative metformin, exerts an anticarcinogenic 
and geroprotective effect in rodents.
Thus, a new cyclic aminobenzimidazole derivative, diabenol, containing a 
guanidine group, combines pharmacological effects characteristic for both bigu-
anide derivatives (reduction of hyperglycemia and liver glycogenolysis, improved 
glucose tolerance, anticarcinogenic and geroprotective effects) and for sulfonylurea 
derivative gliclazide (restoring insulin secretion, antiplatelet, and antiradical activ-
ity). It is quite possible that all of the identified effects are not a manifestation of the 
multi-target action but are pleiotropic effects of diabenol.
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